Diabeloop announced today that it entered into global development and commercial agreements with insulin delivery technology developer SOOIL.
Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020.
Get the full story at our sister site, Drug Delivery Business News.